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Abstract
Effectiveness of Continuous Glucose Monitoring in Children, Adolescents and Young Adults
with Poorly Controlled Type 1 Diabetes

Kevin R. Lewis

Background
Type 1 diabetes is the second most common chronic illness seen in children. Children,
adolescents and young adults with type 1 diabetes are provided care in programs with diabetes
educators, nurses, nurse practitioners, physicians, dietitians, and many other specialists. Even
though children, adolescents and young adults receive care from many providers, their diabetes
is often not in good control. In the last 10 years a new device called a continuous glucose
monitor has been developed for use with people with diabetes. This new device documents the
blood sugar levels in people with diabetes between finger stick blood sugar tests.
Objectives
This study utilized a newly developed investigational continuous glucose monitoring device in
children, adolescents and young adults ages 7-21 who had very high blood sugars and a
hemoglobin A1c of 9% or greater. The rationale was that if the participants could see their blood
sugars in between regular testing, it would help them to lower their blood sugars. The study used
the Family Approach to Diabetes Management model to improve adherence to wearing the CGM
monitor. The primary outcome of the study was to improve HbA1c by at least 0.5%. Secondary
outcomes of the study included: adherence to wearing the continuous glucose monitor, adherence
to blood sugar testing, decrease in hypoglycemia, and change in quality of life indicators.
Design
This study used a prospective, one group, pre and post-test pre experimental design with a
convenience sample of patients. The 12-week intervention tested the efficacy of a newly
developed continuous glucose monitor on glycemic control. Participants were seen every four
weeks during the study. At the baseline visit, demographic data were collected and participants
completed the Quality of Life for Youth form. Patients and families were taught to use the
continuous glucose monitor, and the basic concepts of the Family Approach to Diabetes
Management Model. Baseline HgA1c levels were determined as well as reported and actual
frequency of blood testing was determined. Data collected at the subsequent visits included
downloads from of the continuous glucose monitor, home finger stick blood glucose monitor and
completion of a qualitative interview about experiences with the monitor use. In addition, data
collected at the final study visit included collection of HbA1cs and completion of the Quality of
Life for Youth forms.

Subjects
Thirty-three subjects enrolled in the study. Twenty-one (63.6%) completed the final study visit
at 12 weeks. The mean age of the subjects was 15.57 years with a range of 11 to 20 years. Of
the 21 that finished the study, 47.6% were male and 52.4% were female.
Results
There was a clinically and statistically significant improvement in HbA1c from baseline by
1.1095% (SD=1.9321) p=0.016. Fifteen of the participants (71.4%) had an improvement of
greater than 0.5% in HbA1c. Participants wore the CGM monitor a mean of 51.1429 (SD
=20.68543) days with a range of 21 to 81 days. For this study, wearing the monitor any part of
the day was counted as one day. The participants wore the monitor a mean of 4.262 days a
week. At the end of the study, two participants were identified as manipulating the CGM device
and did not provide accurate finger stick blood glucoses to calibrate the monitor. The change in
HbA1c was recalculated removing these participants from the analysis resulting in, a mean
improvement of 1.4579% (SD=1.6711) p=0.001. While there were no significant differences in
quality of life among the six subscales evaluated, there was a trend in improvement of areas of
symptoms, treatment, parental issues, worry, and health. Data derived from qualitative
interviews demonstrated an improved attitude among the participants and improved parent child
interaction.
Conclusion
Continuous glucose monitoring with the Family Approach to Diabetes Management model was
effective in improving glycemic control with children, adolescents and young adults with poorly
controlled diabetes.

Running head: Effectiveness of Continuous Glucose Monitoring

4

Acknowledgements
I would like to thank all of the people that gave me support and encouragement over the years to
further my education and make this project work.
•

To my committee members, Dr. Susan McCrone, Dr. Pamela Deiriggi, and Dr. Sachin
Bendre I thank you for all of your support during extended timeline to finish this project.
To Dr. McCrone, I thank you especially for all of the many countless hours that you put
into helping me make this project succeed.

•

To Dr. Stacey Culp for your statistical support and guidance.

•

To my colleagues, especially Dr. Amanda Dye for her support.

•

To our clinic nurses and staff for all of their work and assistance in with the study visits.

•

To the WVU Department of Pediatrics, Charleston Division for their support and
allowing me to complete this project.

•

To Medtronic Minimed for their generous grant of continuous glucose monitors and
sensors for my study. Without their grant, this study would not have happened.

•

To Charleston Area Medical Center Research and Grants Administration for their
financial grant to make this project a success.

•

To my partner Adam Viski, I thank you for all of your support, love and persistence that I
would finish this project. I thank you for not getting discouraged with me over the many
hours of being ignored while I stared at a computer screen for numerous evenings over
the last several years of my program. I thank you for all of our road trips where you said
you would drive so I could work on schoolwork.

•

To my parents Gerald and Gloria Lewis, I thank you for instilling in my head the value of
an education at a very young age.	
  

Running head: Effectiveness of Continuous Glucose Monitoring

5

Table of Contents
Abstract

2

Acknowledgements

4

Table of Contents

5

Table of Tables

7

Table of Appendix

7

CHAPTER 1 INTRODUCTION
Background and Significance

8

Theoretical Framework

10

Application of Theory

11

Problem Statement

14

CHAPTER II REVIEW OF THE LITERATURE
Search Strategy

16

Clinical Appraisal

17

Synthesis

20

Discussion

21

Conclusion

22

Project Objectives

22

Stakeholders

24

Congruence of Organizational Strategic Plan to the Capstone Project

24

CHAPTER III METHODOLOGY
Evidence Base Project

26

Procedures/Protocol

27

Running head: Effectiveness of Continuous Glucose Monitoring

6

Timeline of Project

30

Resources

32

Financial Plan/Budget

33

CHAPTER IV RESULTS
Evaluation

34

Demographics

34

Glycemic control

37

Adherence

38

Hypoglycemia

39

Quality of life questionnaires

40

Qualitative questionnaire findings

40

CHAPTER V SUMMARY, DISCUSSION, IMPLICATIONS
Congruence with Theoretical Model

43

Discussion

44

Recommendations

48

Conclusion

48

REFERENCES

50

Running head: Effectiveness of Continuous Glucose Monitoring

7

Table of Tables and Appendices
Table 1. Capstone Timeline

29

Table 2. Gender

35

Table 3. Race

35

Table 4. Other Health Conditions Reported

35

Table 5. Insulin Delivery Method

36

Table 6. Primary Caregiver

35

Table 7. Family Description

35

Table 8. Baseline Demographics for Participants that Completed the Study

37

Appendix A Evidence of Key Site Support

52

Appendix B Continuous Glucose Monitoring Data Collection Tool

53

Appendix C Qualitative Tool

55

Appendix D Capstone Budget

56

Appendix E Agreement for use of Quality of Life Tool

59

Running head: Effectiveness of Continuous Glucose Monitoring

8

Effectiveness of Continuous Glucose Monitoring in Children, Adolescents and Young Adults
with Poorly Controlled Type 1 Diabetes
CHAPTER 1 INTRODUCTION
Background and Significance
Background
Type 1 diabetes is the second most common chronic childhood illness, and it is estimated
that there are 215,000 children under the age of 20 with type 1 diabetes in the United States
(Centers for Disease Control and Prevention, 2011). Type 1 diabetes is a manageable lifelong
chronic disease, and if well controlled, a person can live a long and productive life.
Unfortunately, in spite of aggressive diabetes management strategies, a large majority of
children, adolescents and young adults with diabetes are not adequately controlled (Silverstein et
al., 2005). Poorly controlled diabetes can lead to a number of chronic complications which can
ultimately lead to blindness, kidney failure, nerve damage, and heart disease (Sperling, 2002).
Continuous glucose monitoring (CGM) has been shown to improve glycemic control in children,
adolescents and young adults when worn 6 or more days per week (Juvenile Diabetes Research
Foundation Continuous Glucose Monitoring Study Group, 2009). This study will evaluate the
effectiveness of CGM in children, adolescents and young adults with poorly controlled diabetes
in improving glycemic control, adherence to the diabetes treatment regimen, and quality of life.
The study tested a new investigational sensor that can be worn for up to six days a week.
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Significance
Adolescents are in a time of transition from relying on parents for total care to complete
self-care as an adult. Teenage rebellion can complicate the adolescent’s ability to be successful at
completing all of the tasks associated with the diabetes management regimen. In the past,
adolescents who did not adhere to adequate self-care behaviors have classically been labeled as
non-compliant or difficult to manage.
If optimal care and adherence is not achieved, the patient is at higher risk for developing
both acute and chronic complications of diabetes (Schilling, Knafl, & Grey, 2006). Acute
complications of diabetes can include diabetic keto-acidosis (DKA) and hypoglycemia. While
DKA has a high rate of resolution, approximately 1 in 100 children with DKA will have a poor
outcome including death or permanent disability (Sperling, 2002). Severe hypoglycemia can
also have potentially grave outcomes (Sperling, 2002). Chronic complications of poorly
controlled diabetes can include: retinopathy, neuropathy, nephropathy, heart disease, and
hypertension (Sperling, 2002). While long-term complications may take many years to develop,
once present, they are irreversible and all have permanent lifelong consequences (Sperling,
2002). The goals for glycemic control in the population is an HbA1c level <8% (Silverstein et
al., 2005).
Several factors can be associated with increasing difficulty in managing adolescent
diabetes. Puberty can cause a significant increase in insulin requirements (Sperling, 2002).
Widely varying schedules can necessitate the need for flexible insulin regimens to achieve
glycemic control. Teenage rebellion can complicate an adolescent’s ability to be successful at
completing all of the tasks associated with the diabetes management regimen. Because the needs
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of children, adolescents and young adults with type 1 diabetes are complex, their self-care is best
facilitated by a multidisciplinary team that can address all of the health and psychosocial needs
of children, adolescents and young adults (Sperling, 2002).
Theoretical Framework
Identification of Clinical Problem
Children, adolescents and young adults with type 1 diabetes present unique challenges
that complicate the normal growth and development seen at this age. Diabetes management
including blood sugar testing, insulin injections, and dietary restrictions complicate the daily
activities of these groups. As children grow into adolescents and young adults, these challenges
continue to be more difficult (Schilling et al., 2006). While a number of educational theories
exist to address delivery of diabetes education to patients, none address the complexities of
dealing with children, adolescents and young adults with diabetes and their families as a whole.
The Family Approach to Diabetes Management was developed from a family therapy model
specifically designed to address the patient and the family as a whole (Solowiejczyk, 2004).
Explanation of the Model
The Family Approach to Diabetes Management (FADM) model directly addresses the
problem of poor adherence to diabetes self-care and the family’s integral effect on self-care
behaviors (Solowiejczyk, 2004). Tenets of the model are that diabetes is a complex disease
affecting the whole family, that no other chronic disease places so many burdens on the child,
adolescent and young adult, and that family function has a direct role on outcomes of metabolic
control. The FADM model was developed based on the unpublished findings of work done at
Children’s Hospital of Philadelphia (CHOP) in the 70’s and 80’s using a family therapy
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approach to chronic care. The author of the model, Solowiejczyk, was a member of the original
study group. The staff at CHOP utilized their findings to develop a model that could be applied
to children, adolescents and young adults with diabetes. Unfortunately, these initial findings
were not published, but Solowiejczyk utilized these earlier findings to develop this model. A
major factor was identified that led to a higher likelihood of positive outcomes was that positive
family communication is essential to create behavior patterns that will lead to successful selfcare. Other major determinants of a positive outcome were the mother’s sense of how supported
she felt and the ease of getting the family scheduled for education sessions (Solowiejczyk, 2004).
Clinical assumptions of the model are based on the following factors: the family’s
resources, needs and rules affecting the outcomes for the child, and expectations of self-care.
The patient is the entire family and must be treated as a whole unit. Responsibility for self-care
is not an option, it is the expected behavior (Solowiejczyk, 2004). Parents are the rule makers in
the home; they control the money, food, clothes, car, and recreational activities. Because they
control all of these factors, they need to set expectations for self-care, and also to determine the
consequences for poor self-care behavior. Mismanagement of diabetes should be treated the
same as not doing chores or homework, i.e., you don’t have to like it; you just have to do it. The
main thought is children will rise to the highest level they are asked to achieve.
Theory Application
The populations for the capstone project were children, adolescents and young adults
ages 7-21 with poorly controlled diabetes (HbA1c level at 9% or higher). The intervention
utilizes continuous glucose monitoring to increase awareness of blood sugar patterns so that the
patient and family could have a greater understanding of the implications of the diabetes self-
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management behaviors. In addition to providing a greater understanding of how the person’s
behaviors affects his or her diabetes self-care, the CGM device gives instant feedback in the form
of a real time trend of the individual’s blood sugar values. The family can use these values to
look back at the individual’s day and evaluate how well he or she did in managing the diabetes
that day. The patient and family can utilize the findings to make adjustments to the insulin
regimen utilizing pattern management to adjust the insulin doses to improve the glycemic
control.
Diabetes affects the family as a whole. In a large majority of cases where the
child/adolescent/young adult is in poor glycemic control, the patient and parent interactions
focus on negative feedback from the parent and are often seen as nagging. For example, if the
individual has a high blood sugar, the parent and their child/adolescent/young adult may be in a
disagreement because the blood sugar is elevated instead of utilizing this moment as a learning
point for the dyad. For example, if the patient did not take his or her insulin, the parent can put a
plan in place to help make sure someone helps him or her get the proper dose of insulin at the
right time. If the blood sugar is elevated because the patient did not calculate the proper dose of
insulin, the parent can review each of the foods that the patient commonly eats and generate or
devise a quick list of common foods and amount of insulin based on each usual serving he or she
eats. The goal of the model is to refocus the family to positive communication patterns, to set
reasonable and attainable goals for self-care measures, and to have a plan for consequences of
undesirable behaviors.
Past studies have shown that benefit from use of CGM monitors is only obtained when
the monitor is worn at least 70% of the time (Wilson et al., 2011). Because the intervention is
dependent upon the use of the device to be successful, the family was asked to meet together on
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a regular interval to discuss the diabetes care behaviors and come up with a plan based on how
the family perceives the patient is doing based on blood sugar patterns. Initially, the family was
asked to meet each evening for 5-10 minutes to review the blood sugars on the CGM device. The
family would then reflect on the pattern of blood sugars and identify problems with particular
foods or missed insulin doses. The treatment team asked the family to meet daily until both the
patient and parent agreed that the individual was doing well with insulin dosing and calculating
insulin doses based on food consumption. If the patient was having trouble with dosing of
insulin or testing the blood sugar and calibrating the sensor, the team would give them strategies
to improve this behavior, such as the family sitting together each time the patient tested the blood
sugar, determining the insulin dose together, and supervising or giving the insulin dose.
Once they were meeting the basics of diabetes care, the family could space these
meetings out to every three days. The meetings every three days were used to reinforce self-care
activities and to review the blood sugars to adjust the insulin doses based on these patterns.
Once the family was meeting the goals of blood sugar control and self-care activities, they were
able to space the family meetings out to once a week. The purpose of this meeting was to review
the self-care measures and glycemic control. If the parent found that the patient was not doing
well, the family meetings needed to be moved back to every three days or even daily.
In the event that the child/adolescent did not meet the basics of self-care even with daily
meetings, the parent needed to be willing to implement consequences for poor behaviors. These
consequences needed to be age specific and individually tailored. For example, consequences
for older adolescents that wanted to learn to drive or be able to drive their parent’s car could be
the loss of driving privileges for a predetermined amount of time. For younger adolescents it
could be tied to money, use of cell phones, computer use or other luxuries that would have a
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negative impact on the adolescent and improve the self-care behaviors. The consequence were
time-limited and appropriate, for example, loss of cell phone use for one week If the behavior
improved, the patient could get the privilege back the next week. If not, he or she would lose it
for another week. The primary purpose for the use of the model was not only to improve family
communications, but also to improve diabetes self-care behaviors and ultimately increase the use
of continuous glucose monitoring.
Importance/Relevance to Nursing Practice
Healthcare of children, adolescents and young adults with type 1 diabetes has significant
implications for nursing practice. Care is best provided by a multidisciplinary team that includes
diabetes nurse educators and nurse practitioners. If optimal care and adherence is not achieved,
the patient is at higher risk for developing both short and long term complications of diabetes
(Schilling et al., 2006). The Family Approach to Diabetes Management (FADM) model is
directly applicable to the study population and the goals of increasing adherence to tasks
associated with diabetes self-management (Solowiejczyk, 2004). This model was developed by
the Solowiejczyk, utilizing the originally developed concepts from earlier studies that were
unpublished (Solowiejczyk, 2004).
Summary
The FADM model was designed to treat diabetes in children as a family problem and not
just a disease of the child. The model provides a framework to promote family communication
with the ultimate goal of increasing adherence to diabetes self-care tasks. A major problem
identified in children, adolescents and young adults with type 1 diabetes is poor adherence to
their diabetes care. This model was used to promote the use of the CGM monitor during the
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study. The families were taught at visit one to have regular family meetings based on blood
sugar goals for the patient. They also developed consequences that the patient and family agreed
to put into place for unacceptable behaviors related to diabetes care. The family was encouraged
to track the use of the model by entering the family meetings into the patient diary.
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CHAPTER II REVIEW OF THE LITERATURE
Project Description
Introduction and Background
In the past 10 years, continuous glucose monitoring has been developed with the goal of
improving the outcomes in people with diabetes (Blevins et al., 2010). The standard of diabetes
care includes traditional diabetes education intervention and management in a multidisciplinary
setting (Sperling, 2002). Some data are available on the efficacy of continuous glucose
monitoring on improving outcomes of diabetes care. Studies have been conducted to evaluate
the efficacy of CGM in children, adolescents, and adults with diabetes (Blevins et al., 2010).
However, a gap exists in the literature as to whether CGM improved HbA1c in children,
adolescents and young adults with poorly controlled diabetes. The review of the literature herein
focused on the following question: In children, adolescents and young adults ages 7-21 with
poorly controlled type 1 diabetes (HbA1c at 9% or higher) does continuous glucose monitoring
improve glycemic control as evidenced by HbA1c, adherence to diabetes self-care behaviors, and
quality of life.

Search Strategy
A comprehensive search strategy was developed to locate the best evidence for
effectiveness of continuous glucose monitoring use in children, adolescents and young adults
with poorly controlled type 1 diabetes. and its effect on lowering HbA1c. The search included a
search of: National Guideline Clearinghouse, The Cochrane Library, Academic Search
Complete, PubMed, and CINAHL. These databases were searched using the key words:
continuous glucose monitoring, diabetes, children, and adolescents. There was no limit on
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geographic location, but studies were limited to the last eight years. The search was limited to
English language and to subjects less than 18 years of age. The initial search that included all of
the key terms returned 45 articles. Further searches were completed using combinations of key
words including continuous glucose monitoring and diabetes, which returned 437 papers. No
clinical practice guidelines specifically for use of CGM in children or adolescents were found,
however an adult guideline with a small pediatric section was identified. The search was limited
to articles that were systematic reviews, randomized controlled trials, non-randomized controlled
trials, and cohort studies that were published from 2005 to 2013. Snowballing was utilized to
find further studies, but none were found. The titles of the 437 papers that were found were
manually scanned for applicability to the search. Finally, seven studies were included in the
review, two systematic reviews, and six randomized controlled studies. These studies were
included because they had pediatric subjects who utilized the continuous glucose monitor and
had outcomes relevant to this project.
Critical Appraisal
A critical appraisal of each of the eight articles was completed utilizing appropriate
appraisal tools. The systematic reviews were appraised utilizing the Scottish Intercollegiate
Guideline Network form for systematic reviews. The six randomized control trials were
appraised utilizing the SIGN (2012) form for randomized control trials. The first systematic
review evaluated outcomes of glycemic control in children, adolescents, and adults from six
studies (Joubert & Reznik, 2011). All of the six studies focused on the use of insulin pump
therapy with CGM monitoring and showed improved outcomes of glycemic control compared to
standard and multiple injection therapy. Secondary findings of most of the studies showed
improvement in HbA1c for participants that wore the device more than 70% of the time. This
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review is limited in application to this study because the focus is on concurrent use of CGM and
Continuous Subcutaneous Insulin Infusion (CSII) in adolescents.
The other systematic review evaluated a total of 14 studies (Wojciechowski, Ryś,
Lipowska, Gawęska, & Małecki, 2011). Eight of these studies were based on current CGM
systems (worn continuously), which gives the patient instant information. Six studies were
based on older retrospective systems for diagnostic intermittent use. The studies that evaluated
the current continuous CGM system showed an HbA1c improvement ranging from 0.15-0.43%,
the average improvement in this group was 0.27%, with the lowering of both groups’ HbA1c by
0.26% (p < 0.0001) (Wojciechowski, Ryś, Lipowska, Gawęska, & Małecki, 2011). The authors
found inconsistencies in ways that hypoglycemia and hyperglycemia were reported making
secondary analysis of the data difficult. Due to the variety of ways in which the studies reported
the ages, the authors were not able to report findings in the 8 to 18 year age range. These studies
showed favorable findings for use of CGM when compared to standard finger stick blood sugar
testing alone.
Two of the RCT studies (Battelino et al., 2011; Raccah et al., 2009) evaluated the use of
CGM in conjunction with insulin pump therapy also known as continuous subcutaneous insulin
infusion (CSII). Both studies evaluated children, adolescents and adults. Each study lasted one
year and evaluated HbA1cs. They both compared a group using continuous subcutaneous insulin
infusion with CGM technology to a control group of patients on injection therapy that were not
using CGM. In each of these studies, the CGM group showed improvement in HbA1c by 0.51%
(p < 0.001) and 0.27% (p = 0.008), respectively over the group on injection therapy that did not
use the CGM monitor.

Running head: Effectiveness of Continuous Glucose Monitoring

19

The Juvenile Diabetes Research Foundation (JDRF) CGM study group evaluated 322
adults and children with HbA1c levels ranging from 7-10% in a RCT utilizing CGM
(Tamborlane et al., 2008). They found that adults had a significant lowering in HbA1c levels.
Children ages 8-14 had less hypoglycemia (even though the study was not designed to measure
hypoglycemia significance), but did not have an improvement in HbA1c levels (p = 0.29).
Adults (> age 25) that had improvement in HbA1c levels utilized the CGM device six or more
days per week, those ages 15 to 24 utilized the device 30% of the time and children ages 8 to 14,
50% of the time. Strength of the study was that a large number of adults were evaluated during
the study. The small number of children in the study limited the study, and there was no
secondary analysis of subsets of the population done to evaluate outcomes based on the amount
of time that the device was used.
The Juvenile Diabetes Research Foundation (JDRF) CGM study group in another study
evaluated 129 participants ages 8 to 69 years with HbA1c <7.0 %; they compared a treatment
group that utilized a CGM monitor to a control group that did standard finger stick blood sugar
testing alone (Beck et al., 2009b). The investigators evaluated the outcomes at six months for
each of the groups. The participants had less time at hypoglycemia compared to the control
group, but the difference was not statistically significant (p = 0.43). The investigators found
reduction in HbA1c, a difference of improvement of 0.34% compared to the control group,
without worsening of hypoglycemia (p < 0.001). Strengths of the study included the large study
population and comparable control group. The weakness of the study was that only patients that
were very well controlled were sampled, and there was no stratification of HbA1c by ages.
The remaining two RCT studies evaluated the use of CGM in patients with type 1
diabetes that were well-controlled (Battelino et al., 2011; Beck et al., 2009a). The first study
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evaluated 120 adults and children and showed that both children and adults had improvement of
HbA1c of 0.27% (p < 0.001) and less hypoglycemia with use of CGM when compared to the
control group (p < 0.001). The second study also showed that participants had less time spent in
hypoglycemia compared to the control (p = 0.009) and improved HbA1c levels >/= 0.3%
(p=<0.001) with CGM use. This study showed improvement in HbA1c when the device was
worn 6 or more days a week. Strengths of the studies included the duration of 26 weeks, and
they were designed to evaluate hypoglycemia and HbA1c improvement. A weakness of the
studies was the difficulty in evaluating outcomes specifically in children based on how the
patients’ ages were stratified in the data analysis.
Synthesis
All of the studies reviewed evaluated children with diabetes and CGM use. Two
systematic reviews and 5 RCTs showed improvement in HbA1c levels with CGM use in children
and adolescents. Two RCTs (Battelino et al., 2011; Beck et al., 2009b) showed decreases in
hypoglycemia with CGM use while improving HbA1c levels. One of the studies (Tamborlane et
al., 2008) showed no significant improvement in HbA1c levels. None of the studies evaluated
the use of CGM in patients with HbA1c > 10%. These studies show the benefits of CGM in
children, adolescents, and adults who wore the device 6 days a week or more (Beck et al.,
2009a).
One of the systematic reviews found a higher percentage of patients reaching a goal of
HbA1c with an intervention of continuous glucose monitoring (CGM) and a secondary effect of
less hypoglycemia (Wojciechowski et al., 2011). The second systematic review found a
lowering of HbA1c of 0.5 to1.0% without increased risk of hypoglycemia (Joubert & Reznik,
2011). Each of the systematic reviews included studies with both adults and children. One RCT

Running head: Effectiveness of Continuous Glucose Monitoring

21

evaluated factors affecting improved outcome of HbA1c, and found that improved HbA1c was
seen in patients that wore the sensor >70% of the time (Joubert & Reznik, 2011)). One RCT
showed benefit of CGM in adults that wore CGM, but did not show the same results in children
and adolescents due to their wearing the device less often (Tamborlane et al., 2008). Two of the
RCT studies evaluated the outcome of hypoglycemia in groups, both adults and children, that
were at or close to HbA1c goal and showed less hypoglycemia (Battelino et al., 2011; Beck et
al., 2009b). Two RCTs showed improvement in HbA1c when utilizing CGM with concurrent
initiation of insulin pump therapy (Battelino et al., 2011; Raccah et al., 2009).
Discussion
The literature review identified the need for further research to evaluate the effectiveness
of CGM on adherence to treatment, and improving HbA1c in children, adolescents and young
adults with diabetes, especially those with poor diabetes control. Quality of life is another
variable that needs to be addressed that was not considered in the studies. All but one of the
studies utilizing CGM (Tamborlane et al., 2008) showed statistically significant improvement in
HbA1c levels, but pediatric participants in this study did not wear the CGM on an almost daily
basis. One study found improvement in HbA1c in this population when the CGM was worn 6 or
more days a week (Beck et al., 2009a). The proposed study evaluated the short-term use (12
weeks) of CGM in children, adolescents and young adults with HbA1c levels of 9% or higher.
The potential benefits of this intervention in improving HbA1c levels are important for this
population. While this intervention has been found to improve HbA1c levels in children,
adolescents and young adults who are at goal of HbA1c or near goal, this was the first study
undertaken in children, adolescents and young adults with very high HbA1c levels.
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Conclusion
Children, adolescents and young adults with diabetes present unique challenges that are
not seen in adults. In addition to everyday challenges of diabetes self-management, normal
issues observed in growth and development can complicate the self-care regimen. While
standard diabetes education has been shown to improve HbA1c levels in general, HbA1c levels
in at-risk populations have continued to rise in spite of standard diabetes education.
Improvement of metabolic control in diabetes is important in decreasing the risk of potential
complications including: retinopathy, nephropathy, neuropathy, and heart disease. HbA1c
improvement has been shown to significantly decrease the risk of these complications.
A systematic review of the literature has shown that continuous glucose monitoring is
effective in lowering HbA1c levels. Further studies need to be completed to verify the
effectiveness of this intervention in lowering HbA1c levels in children, adolescents and young
adults with very high HbA1c levels. Due to the higher costs associated with CGM, long term
studies need to be done to show the benefits, especially in high-risk populations benefit. While
there are no long-term studies to evaluate the decrease in chronic complication of diabetes, shortterm improvement may suggest a decrease in long-term risk of complications. Such studies could
show benefit to this at-risk population and justify that insurance companies cover this therapy as
standard of care.

Project Objectives
The first objective was to improve HbA1c levels in children, adolescents and young
adults with poorly controlled diabetes by using continuous glucose monitoring.
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This study was done at WVU Pediatric Endocrinology clinic in Charleston, WV. The
goal was to recruit 40 patients ages 7-21 with an HbA1c level of 9% or higher. HgA1c was
measured at baseline and again at a 3-month visit to evaluate the change in HbA1c. The research
plan included strategies to help the family and participant meet the goals of wearing the
continuous glucose monitor 6 or more days a week. The goal was to improve HbA1c, thereby
decreasing risk of long-term risk of complications. A lowering of HbA1c level by 0.5% is
considered to be clinically significant.
The second objective was to increase adherence to the diabetes regimen by using
continuous glucose monitoring. The team measured adherence to the diabetes regimen at
baseline and at one, two and three months to evaluate the outcome. The team utilized the Family
Approach to Diabetes management model to improve the patient’s likelihood of adhering to
finger stick glucose monitoring. This approach needed to be employed to increase the likelihood
that the participant would adhere to testing the blood sugar three or more times a day. The
research plan included strategies to help the family and participant meet the goals of increasing
blood sugar testing (adherence). The goal was to improve testing to three or more times a day.
The third objective was to improve quality of life in children, adolescents and young
adults with poorly controlled diabetes by using continuous glucose monitoring.
The team measured Quality of Life utilizing the Quality of Life Short form at baseline
and at three months. The Family Approach to Diabetes management model was used to improve
the patient’s likelihood of adhering to the use of the continuous glucose monitor. This approach
needed to be employed to increase the likelihood that the participant would use the device 6 or
more days a week, which was shown to improve outcomes in previous studies. The evaluation
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of quality of life was a secondary objective of the study. The research plan included strategies to
help the family and participant meet the goals of wearing the continuous glucose monitor 6 or
more days a week. The goal was that it would improve the quality of life for participants.
The fourth objective was to help the participants deal with the increased pain associated
with use of the CGM sensor, finger stick blood sugar testing, and insulin injections.
The goal was to increase the participant’s adherence to the treatment regimen by
increasing blood sugar testing, insulin injections and use of the CGM six or more days a week.
The team gave the patient tips for decreasing pain associated with use of diabetes related tasks in
the form of a handout to identify resources available. Participants were given lidocaine /
prilocaine cream at time of entry into the study to be used for pain associated with insertion of
the CGM sensor. The goal was for participants to have increased blood sugar testing, increased
self-reporting of insulin injections and use of CGM device 6 or more days a week by download
at the one month follow up.
Congruence of Organizations Strategic Plan to Project
Children, adolescents and young adults with diabetes are seen for regular follow up every
three months in the pediatric endocrine clinic. Patients that have HbA1c levels at 10% or greater
are seen at a more frequent interval of every 4 to 6 weeks. Several years ago, the organization
held a high-risk clinic for children with elevated HbA1c levels. The program included diabetes
educators, a dietitian, and a psychologist. The program only lasted one year. The patient show
rate for the clinic was very low and after the year, the clinic could not be continued. The WVU
pediatric endocrine practice currently follows 600 children with diabetes, with a large majority of
these children being adolescents and young adults. In the practice, a significant number of these
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adolescents have HbA1c levels greater than 8% and a number are greater than 10%. The
practice has approximately 130 children, adolescents and young adults with HbA1c level at 9%
or greater. The clinic is located in the Department of Pediatrics in the WVU School of Medicine,
Charleston Division. The organizations mission includes patient care, research and service. The
organization is supportive of the project and will allow adequate time and resources to make the
project successful (Appendix A).
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CHAPTER III METHODOLOGY
Project Design
Evidence Based Project/Intervention Plan
This practice change project used a prospective, one group, pre and post-test pre
experimental design, with a convenience sample of patients (Polit, D. F., 2008). Because this is
a practice change, there was no control group. The practice change intended to place 40
participants on CGM for three months to compare the primary outcome of HbA1c at baseline
and at 3 months. In addition, quality of life utilizing the Diabetes Quality of Life in Youth Short
Form (Skinner, Hoey, McGee, & Skovlund, 2006) was to be measured at both time points. The
use of the Family Approach to Diabetes Management model was evaluated at each visit by
reviewing the diary of visits. In addition to these measurements, other indicators of adherence
including number of blood glucose tests per day and total amount of insulin taken daily (selfreported) was measured. The demographic data included age, gender, length of time since
diagnosis of type 1 diabetes, family support system, family dynamics, and who was the primary
caregiver (see Appendix B).
Sample
A convenience sample of 33 participants was recruited from the WVU Pediatric
Endocrinology Clinic in Charleston WV. Participants were ages 9-20 years with type 1 diabetes
and HbA1c 9% or greater. Twenty-one of the participants completed the study. Parents of
patients under 18 signed a consent form and patients an assent form. Patients over 18 signed a
consent form.
To increase the likelihood of participants would return for follow up study visits, the
study offered an incentive program for each study visit completed. The incentive was $20 for
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the baseline visit and for each of the follow-up visits. These incentives were in the form of WalMart gift cards. This was to help offset the costs of travel to participate in the study.
Procedures/Protocol
Participants who met inclusion criteria completed consent/assent forms and a baseline
HbA1c was drawn. Data for the number of blood sugar tests done daily were obtained from
blood glucose meter downloads, and the total amount of self -reported insulin taken during the
day was recorded. The Quality of Life in Diabetes Youth Short Form was administered.
Participants were then instructed on the use of the Medtronic Guardian CGM device and Enlite
sensor. The Guardian CGM system is an FDA approved device that is to be used as an adjunct
to regular blood sugar testing. The Enlite sensor is a minimally invasive sensor that works with
the Guardian device to determine the patient’s blood sugar. The device is investigational and
does not currently have FDA approval for sale in the US, although the device is approved for use
in 35 other countries. The device does not pose a significant risk to the patient, is minimally
invasive and is used only as a trending device to make insulin adjustments. The patient needed
to test his or her blood sugar at least twice a day to calibrate the system in order to get a reading
on the sensor. The patients were instructed to test their blood sugars to determine the accurate
dosing of insulin and any time the CGM monitor identified that they had a low blood sugar (<
70mg/dL). The device was initiated in the office. Follow up visits occurred at 1 and 2 months
after enrollment. At each follow up visit, the investigators downloaded the meter, CGM device,
and made insulin adjustments as needed. Participants then received supplies for the next 4
weeks. The final study visit was at the 3 months. At the final study visit, the investigators
obtained HbA1c levels, downloaded the blood glucose meter to determine frequency of blood
sugar tests, obtained self-reported insulin dosing, and re-administered the Quality of Life in
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Diabetes Youth Short Form. The diary tracking family meetings utilizing the FAMD model
were reviewed at each study visit. After the study was completed, the patients were given their
CGM system, and the investigators attempted to obtain insurance authorization for sensors for
continued use of the device.
Risks
The primary goal of the intervention was to lower HbA1c levels, but lowering HbA1c
carries with it the risk of an increase of hypoglycemic events. The increased risk is associated
with improved control and not the actual use of the CGM monitor. Because previous studies
have shown less likelihood of hypoglycemia with the use of the CGM device, the potential risks
of implementing CGM were considered to be minimal.

Primary Outcomes
The primary study variables were the change in HbA1c levels. Secondary outcomes
included adherence to treatment regimen, and quality of life measures. HbA1c levels were
determined by point of care testing (POCT) in the clinic. The HbA1c level was drawn at
baseline and at three months with a goal of at least 0.5% improvement in control as being
clinically significant. The HbA1c levels were done using the Siemens DCA Vantage POCT
system. This system has previously been evaluated and determined to meet the guidelines for
glyco-hemoglobin standardization (Battelino et al., 2011). HgA1c data were analyzed using a
paired t-test. Adherence to treatment regimen was evaluated by using data downloaded from the
participants home blood glucose monitor and from the CGM monitor. These data were analyzed
using a repeated measures ANOVA test.
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The study evaluated adherence to finger-stick blood sugar testing by recording the
number of blood glucose tests done each day based on the 30-day average from the home meter
download. CGM adherence was evaluated by recording the number of hours the patient wore the
device from the CGM monitor data. These data were collected at monthly follow up visits and
analyzed using a repeated measures ANOVA test.
The CGM downloads were evaluated by the number of hypoglycemic events recorded.
The number of these events in the patient diary was then compared to the patient diary to
evaluate the number of hypoglycemic events, duration of hypoglycemic events, and the number
of hypoglycemic events that required assistance to treat.
Quality of life was measured utilizing the Quality of Life in Diabetes Youth Short Form
(Skinner et al., 2006). A previous study of 2,077 young people found this tool to be both valid
and reliable (Skinner et al., 2006). This is a 22-item form that was developed from an original
55 question Diabetes Quality of Life Youth Form; the old form was lengthy and redundant. This
new form can be completed by the participants in about 5 minutes. The researchers found a
statistically significant correlation between the new form and the older lengthy form in all areas
except impact on activities. The subscales for form include impact of symptoms related to
diabetes, impact of treatment, impact of activities, parent issues, worries about diabetes, and
health perception. The answers are scored on a likert scale of 0-4 with a higher number meaning
worse quality of life in that area. The health perception is scored from 1-4 with a higher number
being worse. This form was administered at the initial and three-month final study visit. The
Novo Nordisk study group holds the copyright for this form. There was no charge to use the
form for the study and data use agreement was in place and approved. A paired t-test was used to

Running head: Effectiveness of Continuous Glucose Monitoring

30

analyze the quality of life data. The Family Approach to Diabetes Management model was
evaluated by diaries the patients completed for review at each at study visit.
Conclusion
Continuous glucose monitoring has the potential to add a valuable tool to treat what has
traditionally been described as a difficult group of patients. In spite of comprehensive diabetes
education and treatment, HbA1c levels continue to rise in this group, and other interventions in
the past have shown little improvement (Silverstein et al., 2005). This study evaluated the
primary outcome of glycemic control. It also evaluated secondary outcomes including:
adherence, quality of life and qualitative outcomes.
Timeline of Project Phases
Clinical Initiatives Utilizing the Logic Model
The logic model was revisited and utilized to develop the clinical initiatives, see Table 1. The
clinical initiatives were developed for use in the study to evaluate the effectiveness of continuous
glucose monitoring for children, adolescents and young adults ages 7 to 21 with poorly
controlled diabetes (HbA1c of 9% or greater).
Table 1
Project Timeline
Item to Be Addressed
Obtain grant funding
for CGM monitor and
supplies

Specific Plan
Applied for grant
funding from
Medtronic diabetes
and CAMC research

Timeline
Grant was secured by
both agencies in
December 2012

Comments
Late change in
protocol required
additional time with
IRB to approve the
use of an
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investigational device.
Final grant was
received from CAMC
Research Institute to
cover study costs and
patient incentives.

Obtain permission for
use of Quality of Life
in Diabetes Youth
Short Form

Completed

Emailed copyright
holder to clarify that
the correct version
was in the agreement.

Develop education
Using the FADM
plan for FADM model model, we will
for staff
educate the nursing
staff on how to use
the model to educate
the families when
teaching them the
CGM device

The nursing staff was
trained in using the
FADM model during
the study.

Needed to educate the
staff on how to
educate the family to
buy into the model for
success.

Develop capstone
plan to present to
committee

Plan developed by the
end of Nursing 793

Plan completed by
5/15/2012

Present capstone plan
to DNP Capstone
committee

Present plan to
committee chair and
members for approval

Plan was presented by
7/15/2012

Submission to IRB

WVU IRB in was the
primary Morgantown
IRB, with secondary
approval needed from
Charleston IRB

November 30, 2012

Recruit subjects to the
study, and complete
first visit (two groups
of 20 for three
months)

Patient were
identified from POCT
labs done in office

1/1/2013 to 7/30/2013

Participants seen at

Participants seen at 1
and 2 month follow
up visits where CGM
and blood glucose

2/1/2013 to 9/30/2013

follow up visits

Email confirming use
of the form after
completing of use
agreement.

There was delay
related to the use of
an investigational
device and the
requirement to get
approval through two
IRB’s.

Running head: Effectiveness of Continuous Glucose Monitoring

32

testing data was
obtained.
Final visit for study

Final data collection
obtained for all
participants

By 9/30/2013

Data analysis

By 10/15/2013

completed

Data analysis
completed with
capstone chair,
committee members
and statistician input

Presentation of

Final presentation

12/6/13

capstone to committee

Resources – Personnel, Technology, Budget
Costs Associated with the Study
There were a number of direct and indirect costs associated with this study. The
Medtronic Guardian continuous glucose monitors and Enlite sensor was provided by a grant
from Medtronic. Other costs associated with the study included HbA1c levels done at baseline
and 3 months for all 21 participants. Nursing time for each participant to teach the CGM device
was estimated at 1.5 hours for each participant starting into the study. The investigators time
and medical assistant’s time to download the monitors were donated by the Department of
Pediatrics and were not calculated into the costs of the study. The study also provided lidocaine /
prilocaine cream free of charge for each of the participants to decrease the pain associated with
the insertion of the CGM sensor. The study also budgeted a nominal amount for the investigator
to travel to a meeting to disseminate the research findings. (Appendix D)
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Sources of Study Funding
The majority of the funding for indirect costs for the study was provided in the form of
grant for study supplies from Medtronic. Medtronic Diabetes approved a grant for the Guardian
Continuous Glucose Monitoring System, Enlite CGM sensors and sensor inserters for 21 of the
participants. The funding to cover HbA1c levels, patient visit incentive and incidentals came
from the Charleston Area Medical Center Research Fund.
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CHAPTER IV RESULTS
Introduction
The goal of this study was to evaluate the effectiveness of continuous glucose monitoring
(CGM) in children, adolescents and young adults ages 7 to 21 years with poorly controlled type
1 diabetes (HbA1c level at 9% or greater). The primary outcomes that were measured included
glycemic control (HbA1c), adherence to the treatment regimen, hypoglycemia and quality of life.
Demographics
The total number of participants recruited into the study who completed the baseline
study visit was 33. A total of 21 participants completed the final study visit. Demographics for
the population were described in Table 2-8. The study had an attrition rate of 36.4%. The
reasons for attrition were as follows: one was not able to complete the visits due to family
illness, two reported skin irritation from the adhesive tape on the glucose sensor, and the other
nine did not continue because they did not wish to continue wearing the monitor. Some of
participants did not like physically wearing the sensor, while others did not like the alarms from
high blood glucose readings. The mean HbA1c of all participants at baseline was 10.515%
(SD=1.4127) with a range of 9-14%. The mean age of all participants was 15.42 years
(SD=2.750) with a range of 9-20 years. There was no difference in age (p=0.691), duration of
diabetes (p=0.698), HbA1c (p=0.655) or weight (p=0.351) between the group that started the
study and those that completed the study. Of the 21 that finished the study, 47.6% were male
and 52.4% were female, 95.2% were Caucasian and 4.8% were African American. The ages of
the group that finished the study ranged from 11 to 20 years of age with the mean being 15.57
(SD=2.657). Household demographics showed 57.1% of the subjects lived in a two parent
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household, 14.3% lived with their mother only, 9.5% lived with their father, 4.8% lived with
grandparents, and the remaining 9.5% either lived by themselves or with a significant other.
Quality of life questionnaires were completed by 100% of the participants who completed the
final study visit.
Demographics
Table 2
Gender

Male
Female
Total

Frequency
10
11
21

Percent
47.6
52.4
100.0

Frequency

Percent

20
1
21

95.2
4.8
100.0

Table 3
Race

Caucasian
African American
Total

Table 4
Other Reported Health Conditions

None
Addison disease
Celiac, hypothyroid
Depression
Hypertension

Frequency
14
1
1
1
1

Percent
66.7
4.8
4.8
4.8
4.8
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Hypothyroid, Cholestero
Hypothyroid, HTN
Microalbuminuria
Total

1
1
1
21

36
4.8
4.8
4.8
100.0

Table 5
Insulin Delivery Method

Injections
Pump
Total

Frequency
9
12
21

Percent
42.9
57.1
100.0

Table 6
Primary Caregiver

Mother
Father
Grandparent
Extended family
Other
Total

Frequency
15
2
1
1
2
21

Percent
71.4
4.8
4.8
9.5
100.0

Table 7
Family Description
Lives with
Mother
Father
Both parents
Grandparent
Other
Total

Frequency
3
2
12
1
3
21

Percent
14.3
9.5
57.1
4.8
14.3
100.0
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Table 8
Baseline Descriptive Statistics Of Subjects that Completed Study

Age
Age at Diagnosis
Years With Diabetes
HBA1c
BG daily test reported
BG test from meter
Insulin TDD
Total

N Minimum Maximum
21
11
20
21
2
17
21
1
17
21
9.0
14.0
21
2.0
9.0
21
.0
6.6
21
.56
1.75
21

Mean
15.57
7.86
7.74
10.600
4.214
2.686
1.0431

Std. Deviation
2.657
3.890
4.200
1.4900
1.7859
1.8610
.28858

Glycemic control
The mean baseline HbA1c of the participants completing the study was 10.600%
(SD=1.49) with a range of 9-14%. The mean HbA1c at completion of the study was 9.490%
(SD=1.47) with a range of 7.3-12.3%. This was a statistically significant HgbA1c improvement
of 1.1095% (SD=1.9321) p=0.016. The change in HbA1c ranged from an improvement of 6.7%
to worsening of 2.5%.
Significance of improvement
Seventeen of the 21 participants demonstrated an improvement in HbA1c. The
improvement in glycemic control ranged from 0.1% to 6.7%. Two of the participants had
improvements of less than 0.5%. Fifteen of the participants had clinically significant
improvement in HbA1c >0.5%. Eleven of the participants had an improvement between 0.5 and
2%. Four of the participants had an improvement of greater than 2%. The mean weight in the
group increased by 1.4134kg (SD=2.7263) p=0.026.

Running head: Effectiveness of Continuous Glucose Monitoring

38

Participants without improvement
Of the four participants who had a worsening HbA1c, two of these participants admitted
to manipulation of the CGM device. One of the participants admitted at the final visit to entering
false lower blood glucose values in the CGM to get the monitor to read lower blood glucose
readings. The other participant admitted to not testing blood glucose values and entering
fictitious readings into the monitor to keep the CGM reading. The HbA1c levels were
recalculated removing these two subjects and a statistically significant reduction in mean
HgbA1c remained. After exclusion of these subjects the mean baseline HbA1c was 10.668%
(SD=1.5532) and improved at final visit to 9.211% (SD=1.2490). The mean improvement of
HbA1c was therefore 1.4579% (SD=1.6711) p=0.001.
Adherence
Adherence was tracked at each visit and at the final visit. Home blood glucose meters
were downloaded at each visit and participants also self-reported the number of times per day
they were testing blood glucose values. Participants self-reported testing their blood sugars
4.214 (SD=1.7859) times a day at baseline with a range of 2-9 times per day. This increased to
4.3095 (SD=2.01542) at visit two and up to 4.342 (SD=2.3336) at visit 3 and slightly down to
4.071 (SD=2.4763) at the final visit. Therefore, a significant difference in self-reported glucose
testing was not demonstrated. Blood glucose monitors were downloaded at each visit and the
baseline mean number of actual tests per day was 2.686 (SD=1.8610) with a range of 0 to 6.6.
The mean increased to 3.781 (SD=2.5459) times per day at visit two, then declined to 3.284
(SD=2.2877) at visit three and down to 2.738 (SD=2.6447) at the final visit. There was no
significant difference in number of blood glucose tests reported by the participants (p=0.745) or
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actual (p=0.121) blood glucose values that were downloaded from the participant’s blood
glucose meter at each visit. When comparing reported number with actual blood glucose testing,
there was significant difference in the number of tests reported versus actual at the baseline visit
(p=0.000), visit three (p=0.017) and the final visit (p=0.006). There was no difference between
the number reported and actual download at visit 2 (p=0.137).
Participants wore the CGM monitor for a mean of 51.14 days (SD=20.865) with a range
of 20 to 81 days. The mean number of total hours the CGM was worn by participants was
820.4286 (SD=437.58423) with a range of 386 to 1674 hours. The mean sensor reading for the
study was 211.05 mg/dL (SD=34.683). There was no correlation between duration of sensor use
and HbA1c improvement (p=0.822). There was no difference in reported total daily dose of
insulin given at each of the visits (p=0.944). Participants were given a diary to complete for
family meetings, significant hypoglycemia, and reasons for not wearing the CGM monitor. Only
two out of the 21 diaries were returned so analysis of the diary data was not possible. None of the
participants required/requested topical lidocaine / prilocaine cream for ease of CGM sensor
insertion.
Hypoglycemia
Hypoglycemia was monitored by self-report at follow up visits and by analysis of CGM
data download. One participant reported having a clinically significant hypoglycemic episode
that required assistance to correct. This participant had two episodes within one week; the
episodes were described as “passing out”. Hypoglycemia was treated successfully with oral
glucose and the participant did not require hospital emergency treatment. When reviewing the
episodes with the participant, they both occurred when the participant was not wearing the
continuous glucose monitor. The percentage of time the CGM area under the curve < 70 mg/dL
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was 0.500 % (SD=0.5030) with a range from 0 to 1.9%. None of the time spent in hypoglycemia
episodes reported by the CGM monitor require assistance to correct.
Quality of life
All participants that completed the final study visit completed all questions in the Quality
of Life in Diabetes Youth Short Form questionnaire. The questionnaire includes six subsets that
impacted diabetes. A higher number in each area is associated with worsening impact. The
baseline mean of symptoms was 4.24 (SD=0.497) and improved to 3.67 (SD=0.532) at the final
visit p=0.319. The baseline mean for treatment was 3.05 (SD=2.062) and improved to 2.43
(SD=2.378) at the final visit p=0.242. The baseline mean for activities was 2.76 (SD=3.419) and
worsened to 3.76 (SD=4.657) at the final visit p=0.144. The baseline mean for parental impact
was 6.48 (SD=3.459) and improved to 5.62 (SD=4.153) at the final visit p=0.204. The baseline
mean for worry was 8.29 (SD=6.908) and improved to 7.10 (SD=7.063) at the final visit
p=0.258. The baseline mean for health was 2.71 (SD=0.845) and improved to 2.48 (SD=0.814)
at the final visit p=0.204. There was significant correlation for all items except for symptoms.
There were no statistically significant improvements in quality of life in the six areas measured
by the questionnaire although improvement was seen in all categories except activities.
Significance may not have been realized because of the small number of subjects or short
duration of the intervention.
Qualitative questionnaire findings
Qualitative Data Analysis:
Qualitative data were collected at each of the follow up visits. Participants were asked if
they met on a regular basis to review and discuss the use of the continuous glucose monitor.
Thirteen (61.9%) of the participants responded that they met on a regular basis. Four (19.0%)
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reported that regular meetings did not occur. Four (19.0%) of the participants lived on their own
and did not have parental involvement in order to be able meet for the family meeting.
Of the thirteen participants who met on a regular basis to discuss glycemic control, selfreported topics of discussion revealed three major themes. The first theme identified was
identification of blood sugar problems that were previously not recognized. Some of the
findings reported included: higher blood glucose values at night which were not known,
hyperglycemia before lunch and dinner, nocturnal hypoglycemia, post-prandial hyperglycemia
and rebound hyperglycemia. The second common theme was seeing the CGM monitor catch
hyperglycemia and hypoglycemia before they occurred. Participants were able to identify causes
of glycemic deviation and the reasons the blood glucoses were going low or high at different
times. The final common theme was the monitor helped keep them on track. This included
noticing how different things affected blood glucose values. Other issues that were discussed
included: family reviewing blood sugars, noting that the participant needed to test more
frequently, and frequent sensor alarms. The families were instructed to determine consequences
for participants that did not wear the CGM monitor on a regular basis. Eleven of the families
reported that their child was wearing the device on a regular basis and did not require
implementation of consequences. Two of the participants did not wear the CGM monitor on a
regular basis, but the families did not implement consequences as directed. Four of the
participants were living independently and did not have parental involvement to implement
consequences. Two of the participants wore the monitor the majority of the time, but the parent
did not review the monitor as was discussed in the treatment plan. These were the two
participants that had manipulated the CGM to provide readings and because of this manipulation,
they were not getting accurate readings.
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Participants were asked how the CGM monitor helped them at each follow up visit. Four
themes were identified during the follow up visits. The first theme was improved attitude toward
diabetes. Parents described the following areas that were related to behavior: improved attitude
overall, changed attitude toward diabetes, making diabetes more tolerable, and improved interest
in other activities. The child parent relationship was described as improved based on the
following descriptions: added security when the child is away from the parent, parental piece of
mind at night, decreased parental nagging, and improved mother/daughter relationships. The
participants state that they feel better while wearing the CGM. They described this with the
following: feels better now that blood sugar is better, knowing what blood sugar is all of the
time, insulin is given more frequently because of increased awareness, it demonstrates how
different foods affect the blood sugar, it helps understand how the blood sugar affects the way
she feels, and they are watching things closer. The participants and parents also felt that the
alarms were helpful to prevent low blood sugars with the predictive alarm, and to treat higher
blood sugars quicker so they don’t stay as high for as long.
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CHAPTER V SUMMARY, DISCUSSION, IMPLICATIONS
Congruence with Theoretical Framework
The Family Approach to Diabetes Management is a behavior modification program
developed to bring families together to encourage children with diabetes to complete the basics
of self-care to improve their self-management skills. This project uses basic concepts of the
framework to involve the family in encouraging the participant to wear the CGM monitor. Past
studies have shown improvement in HbA1c when the CGM sensor is worn for 6 or more days a
week. All participants and families were trained in the basics of FAMD model at the study
initiation visit and encouraged to utilize the concepts they had been taught at each follow up
visits. Eleven of the families reported meeting on a regular basis and encouraged the participant
to wear the sensor on a regular basis. Four of the participants were living on their own and were
encouraged to have their close support system stress for them to wear the CGM monitor. Two of
the participants wore the monitor on a consistent basis, however they manipulated the CGM data
by entering in erroneous blood sugars that caused the monitor to provide false data. This shows
that family involvement is essential to keep the adolescent on track and using the monitor
correctly.
The FADM model can be successfully implemented into an outpatient clinic environment
to help improve the outcomes of adolescents with diabetes. The model can be used to help
encourage regular use of the CGM monitor. With proper presentation and integration into
clinical practice, the FADM model can be seen by the child, adolescent or young adult not as a
punishment, but as an encouragement and expectation to strive to improve their self-care
behaviors. The parents in this study either fully supported the use of the CGM and reported the
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patient wore the monitor all of the time, or the patients were left to monitor their own self-care.
The parents that were not active in their patient’s care during the study reported they were going
to use the model after their last study visit to improve the self-care deficits that were identified in
the study.
Discussion
HbA1c
There was a clinically and statistically significant improvement in HbA1c of 1.1095%
(SD=1.9321) p=0.016 during the 12 week study. At the end of the study, two participants were
identified as manipulating the CGM device and did not provide accurate finger stick blood
glucoses to calibrate the monitor. The change in HbA1c was recalculated after removing these 2
participants from the analysis and there was outliers a mean improvement of 1.4579%
(SD=1.6711) p=0.001. The studies that were identified from the literature search had HbA1c
levels that ranged from no improvement to an improvement of 1% (Battelino et al., 2011; Raccah
et al., 2009; Joubert & Reznik, 2011; Wojciechowski, Ryś, Lipowska, Gawęska, & Małecki,
2011). For this study an improvement of 0.5% was considered clinically significant. Fifteen of
the participants (71.4%) had an improvement of greater than 0.5% in HbA1c. Eleven of the
participants had final HbA1c levels that improved to less than 9%. Two of those participants had
final HbA1c levels in the 7% range. A HbA1c of less than 8% is considered in goal for this age
group (Silverstein et al., 2005). While not all participants had improvement in HbA1c, those that
had clinically significant improvement in glycemic control ranged from 0.8 % to 6.7%. While
the mean improvement of HbA1c was greater than the other studies that were reviewed, the
baseline HbA1c was higher in this study, and therefore had more potential to improve. With

Running head: Effectiveness of Continuous Glucose Monitoring

45

intensification of glycemic control, there is risk of weight gain. The participants had a mean
weight gain of 1.4134kg (SD=2.7263) p=0.026, while the weight gain is statistically significant,
it is not a clinically significant increase.
Adherence
Participants wore the CGM monitor a mean of 51.1429 (SD=20.68543) days with a range
of 21 to 81, for this study wearing the monitor any part of the day was considered as a day for
analysis. Participants wore the monitor a mean of 4.262 days a week. The previous JDRF study
found improvement in Hba1c when the CGM monitor was worn 6 or more days a week (Beck et
al., 2009a). In this study there was no correlation with duration of use of the CGM and the
improvement in HbA1c (Pearson Correlation 0.334) p=0.162. There was no significant change
in number of blood sugar tests (testing reported or actual) during the intervention. The study
goal was to increase the average number of blood glucose tests to an average 3 tests per day.
This goal was met at follow up visits two and three; however the mean number of test fell below
3 per at the final visit. The number of actual tests decreased close to baseline by the final visit.
One concern was that the participants would test less with the monitor and rely on the readings
of the CGM to dose insulin rather than on their home glucose monitor. A significant decrease in
home blood sugar testing was not found to happen during this study.
Hypoglycemia
None of the participants reported having clinically significant hypoglycemia while
wearing the monitor. Significant hypoglycemia is defined as requiring another person to help
treat the hypoglycemia. This does not include symptomatic hypoglycemia that the participants
were able to self-treat and correct on their own. Although, one participant reported report having
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two clinically significant hypoglycemia events during the study, the participant was not wearing
the CGM monitor when he had the events. The CGM downloads reports showed the participants
had blood sugars of <70 mg/dl a mean of 0.5% (SD=0.5030) of the total time the CGM was
worn with a range from 0 to 1.9%. None of the recorded time in hypoglycemia on the CGM
monitor was report as being clinically significant by the participants. Previous studies showed
less hypoglycemia in groups wearing CGM compared to the control groups without CGM
therapy (Battelino et al., 2011; Beck et al., 2009b). Wearing the CGM in combination with
improving glycemic control does not appear to be associated with self-reported clinically
significant hypoglycemia. These findings are similar to those reported in previous studies.
Nevertheless, participants with improved glycemic control need to be aware of increased risk of
hypoglycemia and should monitor their blood glucose and symptoms very closely.
Quality of life
While there were no significant differences in quality of life among the six areas
evaluated, two areas - parental impact and worry about diabetes - had overall higher scores than
symptoms, treatment, activities and health. There was a trend in improvement of areas of
symptoms, treatment, parental issues, worry, and health. The areas related to activities worsened
from the baseline visit. While these trends were identified, none of the changes were statistically
significant. The highest area reported was in worry about diabetes. These areas related to future
issues and concerns such as marriage, children, education, body image and complication from
diabetes.
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Qualitative findings
A majority of families (61.9%) met on a regular basis to discuss the CGM monitor and
the blood sugars. The families that met identified a number of blood glucose problem areas.
They also were able to discover blood glucose problems that were not previously identified or
known. All of the families had been instructed on use of the FADM model. The participants
that did not wear the monitor on a regular basis did not have any consequences or penalties put in
place for poor behavior. The two participants that manipulated the CGM data were the ones that
the family did meet with their child to review the monitor on a regular basis. The families and
participants found the monitor to be helpful in a number of areas. Those that were expected
included more frequent dosing of insulin and detection of high and low blood sugars. The areas
that were reported and not expected were improved attitude and improved parent interaction.
Significance
This study offers evidence that continuous glucose monitoring improves glycemic control
in children, adolescents, and young adults with poorly controlled diabetes with a HbA1c > 9.0%.
This was a short-term 12-week intervention, so it is not known if there would be further
improvement or regression of glycemic control with long-term continual use of CGM. The
attrition rate for the study was high, and so future interventions should include focusing on
improving retention rates in this difficult population. This intervention requires additional daily
activities beyond what the participants had been doing and it may be more work than they are
willing to do. It is possible for participants to manipulate the CGM monitor; close attention
needs to be paid to participants whose family does not meet on a regular basis to monitor their
child’s care. Previous studies found improvement in glycemic control when the CGM monitor
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was worn 6 or more days a week. This study showed improvement in HbA1c when the mean
number of days of CGM was about 4.2 days per week. Although there was improvement of
HgA1c in this study, this improvement was not correlated with duration of CGM use. While
there was one participant that reported significant hypoglycemia during the study, this happened
when the participant was not wearing the CGM sensor. There was no clinically significant
hypoglycemia reported when the participants were wearing the monitor.
Practice recommendations
Prior to this practice change project, CGM use was limited to request by patient or by
recommendation for patients that had significant hypoglycemic events. The project findings
showed that CGM can be successfully implemented in a clinical practice. We are now offering
CGM monitoring to all patients who are not at goal of HbA1c and who have third party payer
coverage for the system. Of the twenty-one participants that completed the study, four of the
participants now have their own CGM monitors. There are a number of clinic patients that were
not in the study that have been started on CGM monitors. While CGM monitoring is being
implemented into our clinic, there is still a limitation with third party coverage, particularly
Medicaid, Chips and West Virginia PEIA. That data from this practice change project will be
used to work with these payers to expand coverage to this vulnerable population.
Conclusions
CGM with the FADM model was effective in improving glycemic control with children,
adolescents and young adults with poorly controlled diabetes. There was a small but significant
increase in weight during the intervention. There was no significant change in total daily dose of
insulin reported, adherence with blood sugar testing or quality of life during the intervention.
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There was no clinically significant hypoglycemia reported during the CGM monitor use.
Qualitative data analysis revealed the participants and their families had improvement in attitude
toward diabetes and improved parent child interactions.
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Continuous Glucose Monitoring Data Collection Tool (Appendix B)

Patient ID: ________________
Age: _______________
Gender: Male ___ Female ____
Pubertal Status: Pre ___ Post _____
Other health conditions:
___________________________________________________________________
Age at diagnosis ________
Number of years with diabetes: ___________
Lives with: Mother _____ Father _________ Grandparent ___________ Extended Family
____________ Other: _________________

Baseline Visit Data:
HbA1c Level: _____________%
Reported number of blood sugar tests per day: ______ Actual from meter: ____________
Total Insulin Dose reported given per day ________ units/kg/day
Quality of Life tool completed: ______
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Visit 2 Data (one month):
Reported number of blood sugar tests per day: ______ Actual from meter: ____________
Total Insulin Dose reported given per day ________ units/kg/day
Reports of Severe hypoglycemia requiring assistance: _______ number of events: ____

Visit 3 Data (two months):
Reported number of blood sugar tests per day: ______ Actual from meter: ____________
Total Insulin Dose reported given per day ________ units/kg/day
Reports of Severe hypoglycemia requiring assistance: _______ number of events: ____
Final Visit Data (three months):
HbA1c Level: _____________%
Reported number of blood sugar tests per day: ______ Actual from meter: ____________
Total Insulin Dose reported given per day ________ units/kg/day
Reports of Severe hypoglycemia requiring assistance: _______ number of events: ____
Quality of Life tool completed: ______
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Qualitative data collection tool patients: (Appendix C)
Participant Name: _________________________________________ Visit:
_____________________

Did you meet on a regular basis to discuss the diabetes regimen?

What did you discuss at these meetings?

Did you implement the consequences for non-adherence? If yes were they successful, if no, why
not?

How do you think the CGM system is beneficial or not beneficial?

Are there any problems you are having with the system?
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Capstone Budget (Appendix D)

BUDGET FOR CONDUCTING STUDY
Effectiveness of Continuous Glucose Monitoring in Children and Adolescents
With Poorly Controlled Type 1 Diabetes

PLEASE ITEMIZE IN DETAIL THE ESTIMATED COSTS TO CONDUCT THIS STUDY.
DIRECT COSTS
Medtronic
Funds

Requested
Donated Costs

PERSONNEL
Consultants/Temporary
(Hourly rate x # of hrs)

$__________

$__________

$__________

$__________

(Hourly rate x # of hrs)

$__________

$__________

Other Contractual Services

$__________

$__________

Consultants/Temporary
(Hourly rate x # of hrs)
Consultants/Temporary

NON-PERSONNEL
Space Rental Charges

$__________

$__________

Equipment
Item #1 (Cost + tax)

CGM Monitor

$__________

$__25980___
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$__________
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$_____

Supplies
Item #1 (Unit cost + tax)
$__36000________

CGM Sensors

Item #2 (Unit cost + tax)

$__________
$__________

$__________

Telephone Costs

$__________

$__________

Printing Costs (# x cost per item)

$__________

$__________

Copier Costs

$__________

$__________

Copy Paper

$__________

$__________

Postage/Fed. Ex

$__________

$__________

Miscellaneous

Software Costs
$__________

$__________

Slides for presentation

$__________

$__________

Other (list each item)

$__________

$__________

Patient Care Costs
Pharmacy/Drugs
$__________

$__1000_____

Laboratory
$__________

$___656______

Lab #1

$__________

$__________

Lab #2

$__________

$__________

Patient Reimbursement
$__________

$___3200_____
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Travel
Travel Related to study conduct

$__________

Presentation Travel (Indicate set amount $1500)
$__________

$__1500_____

TOTAL COSTS REQUESTED
TOTAL COSTS DONATED

$__________

$__6356_____
$ _61980___
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